# APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

> **NCT03386526** · PHASE1 · COMPLETED · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 90 (actual)

## Conditions studied

- Advanced Solid Tumors or Hematologic Malignancies

## Interventions

- **DRUG:** APG-1387 for Injection

## Key facts

- **NCT ID:** NCT03386526
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-21
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-11-30
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386526, "APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03386526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*